Accessibility Menu
Daxor logo

Daxor(NASDAQ) DXR

Market Cap$59.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1985)+189%
5 Year+11%
1 Year-10%
1 Month-3%
$10.20
+5.48%
+0.53Today
Daxor last closing stock price
MetricPriceDate
Last closeUSD 10.202026-08-28
Daxor stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2%USD 10.002026-08-21
1 month-3.13%USD 10.532026-07-29
3 month-0.78%USD 10.282026-05-29
Year to date-30.85%USD 14.752025-12-31
1 year-9.57%USD 11.282025-08-28
3 year+3.03%USD 9.902023-08-29
5 year+10.74%USD 9.212021-08-27
Since inception+188.8%USD 3.531985-07-02

Daxor Financials at a Glance

Market Cap

$59.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$917.26K

Net Income (TTM)

$9.71M

EPS (TTM)

$1.81

P/E Ratio

5.63

Dividend

$0.00

Beta (Volatility)

0.15 (Low)

Price

$10.20

Volume

13,263

Open

$9.67

Previous Close

$10.20

Daily Range

$9.65 - $10.62

52-Week Range

$8.56 - $14.76

Estimated Earnings Date

Aug 31, 2026

DXR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Daxor

Daxor Corporation is a medical device manufacturer specializing in blood volume measurement technology, primarily through its BVA-100 Blood Volume Analyzer. This technology facilitates precise and rapid blood volume analysis, addressing critical needs in healthcare settings like heart failure and critical care. Alongside its core device, Daxor extends services through its subsidiary Scientific Medical Systems, which offers cryobanking for blood and semen.

Products and Services

BVA-100 Blood Volume Analyzer: Accurately measures blood volume within 60-90 minutes.

Volumex Diagnostic Kit: Single-use kit that works with the BVA-100 for blood volume analysis.

Cryobanking Services: Offers long-term storage for blood and semen, including unique frozen blood storage.

Scientific Research Support: Provides resources and support for clinical research using its products.

What Makes Daxor Corporation Special

Daxor Corporation stands out due to its patented BVA-100 system, which offers unmatched precision in blood volume analysis. This technological edge enables clinicians to make more informed decisions in managing conditions like heart failure and determining fluid management in surgical settings. The company's focus on continuous innovation and its integration into hospital systems underscore its commitment to advancing medical diagnostics.

Five Things You Need to Know

The BVA-100 was FDA-cleared in 1997 and offers significant time and accuracy advantages over traditional blood volume measurement methods.

Daxor has strategically invested in research and development, underscoring a commitment to enhancing its product offerings.

The company supports extensive scientific research, leading to numerous peer-reviewed publications and presentations at major medical conferences.

Through its subsidiary Scientific Medical Systems, Daxor provides innovative cryobanking services for long-term blood and semen storage.

Daxor's technology is recognized for its impact on improving outcomes in conditions such as heart failure, critical care, and perioperative management.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Michael R. Feldschuh

Website

daxor.com

Headquarters

Oak Ridge, TN 37830, US

DXR Financials

Key Financial Metrics (TTM)

Gross Margin

-57.45%

Operating Margin

6174.23%

Net Income Margin

6105.29%

Return on Equity

22.50%

Return on Capital

19.97%

Return on Assets

19.93%

Earnings Yield

17.76%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$59.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

5.84M

Volume

13.26K

Avg. Volume

2.27K

Financials (TTM)

Gross Profit

$606.13K

Operating Income

$11.18M

EBITDA

$11.60M

Operating Cash Flow

-$1.23M

Capital Expenditure

-$6.00

Free Cash Flow

-$1.23M

Cash & ST Invst.

$0.00

Total Debt

$112.00K

Daxor Performance Analysis

Daxor annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD -353,357-86.5%
20232023-12-31USD 34,590,261N/A
20242024-12-31USD -135,668N/A
20252025-12-31USD 503,424N/A
Daxor sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-13.0%
Q42024-12-31869.0%
Q22025-06-30-97.4%
Q42025-12-31618.6%
Daxor annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.277.8%
20232023-12-31USD 0.06-95.2%
20242024-12-31USD 0.1182.8%
20252025-12-31USD 1.841560.1%
Daxor sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-147.2%
Q42024-12-31229.4%
Q22025-06-30-116.9%
Q42025-12-312647.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$131.85K

+59.9%

Gross Profit

-$104.64K

-226.9%

Gross Margin

-79.36%

N/A

Market Cap

$59.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.61M

N/A

Employees

37

N/A

Net Income

$9.54M

+187.5%

EBITDA

$9.54M

N/A

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$0.00

N/A

Total Debt

$112.00K

-85.2%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$112.00K

-85.2%

Short Term Debt

$0.00

N/A

Return on Assets

19.93%

N/A

Return on Invested Capital

20.21%

N/A

Free Cash Flow

-$297.47K

+92.2%

Operating Cash Flow

-$297.47K

+92.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NRXPNRx Pharmaceuticals, Inc.
$3.55-1.93%
GEGGreat Elm Group, Inc.
$2.16+0.47%
XBITXBiotech Inc.
$2.27-1.30%
NEPHNephros, Inc.
$4.55+5.57%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$49.82+0.10%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$111.34-0.10%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$38.54+0.02%
INTCIntel
$89.47-0.03%

Questions About DXR

What is the current price of Daxor?

Daxor is trading at $10.20 per share.

What is the 52-week range for Daxor?

Over the past 52 weeks, Daxor has traded between $8.56 and $14.76.

How much debt does Daxor have?

As of the most recent reporting period, Daxor reported total debt of $112.00K.

How much cash does Daxor have on hand?

Daxor reported $0.00 in cash and cash equivalents in its most recent financial results.

What is Daxor’s dividend yield?

Daxor does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services